Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
$588K—$740K-21.4%——————
$32.93M+7.8%$29.11M-2.1%$22.52M+2.1%$37.2M+33.4%$30.56M+19.9%
$1.95M+19.6%$2.21M+91.9%$1.23M+37.2%$1.74M+48.1%$1.63M+69.9%
$30.99M+7.1%$26.9M-5.9%$21.29M+0.6%$35.45M+32.8%$28.94M+18.0%
94.1%-0.6pp92.4%-3.7pp94.6%-1.4pp95.3%-0.5pp94.7%-1.6pp
————$6.74M+118%$4.82M+29.7%$2.36M-14.8%
$15.03M-2.0%$13.75M-9.5%$14.14M+30.4%$23.82M+41.3%$15.33M+11.9%
$8.92M+107%$7.87M+8.1%$7.22M+45.7%$6.7M+22.6%$4.32M+13.0%
$34.45M+45.8%$43.47M+35.9%$31.87M+61.1%$37.08M+36.3%$23.64M+11.2%
-$1.52M-122%-$14.36M-541%-$9.36M-512%$118K-82.3%$6.93M+63.6%
-4.6%-27.3pp-49.3%-41.8pp-41.5%-51.8pp0.3%-2.1pp22.7%+6.0pp
-$498K-169%-$943K-93.2%$29K-72.9%-$2.19M-34.3%$727K+1,069%
-$1.75M-123%-$14.43M-816%-$9.24M-299%$3.75M+385%$7.63M+94.1%
$733K-56.7%-$164K-125%$621K-31.1%$1.3M+540%$1.69M+57.6%
-$4.05M-212%-$11.66M-471%-$8.69M-422%$763K—$3.61M+221%
-12.3%-24.1pp-40.1%-33.2pp-38.6%-50.8pp2.1%+2.1pp11.8%+7.4pp
-$0.04-233%-$0.12-300%-$0.10—$0.02—$0.03+200%
-$1.05M-115%-$12.88M-946%-$8.68M-409%$774K-31.3%$7.21M+54.0%
-3.2%-26.8pp-44.3%-40.1pp-38.6%-51.3pp2.1%-2.0pp23.6%+5.2pp
-$1.52M-122%-$14.36M-541%-$9.36M-512%$118K-82.3%$6.93M+63.6%

FAQ

What is Gyre Therapeutics, Inc.'s revenue?
Gyre Therapeutics, Inc. (GYRE) generated $121.8M in revenue over the trailing twelve months, up 10.5% year over year.
Is Gyre Therapeutics, Inc. profitable?
Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $23.6M over the trailing twelve months, a -19.4% net margin.
What are Gyre Therapeutics, Inc.'s profit margins?
Gross margin is 94.1% and operating margin is -20.6%, with a -19.4% net margin.
What is Gyre Therapeutics, Inc.'s earnings per share?
Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.24.
Where does Gyre Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.